AUTHORS

Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at http://www.bretjenseninvests.com. Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

My Post-Earnings Assessment of 2 Biotech Stocks

Let's look at a couple of companies we have covered on these pages before.

3 Companies Where Insiders Are Buying Near Recent Bottoms

The insider purchases were at an oil refiner, a video game maker and a retailer of recreational vehicles.

Boeing and CVS: Two Sagas Worth Tracking, But Just One Worth Playing Right Now

With all the unknowns surrounding Boeing it's way too early to take a position in the aircraft maker; the same is not true with CVS.

U.S. Remains Best House in an Increasing Beleaguered Neighborhood

Economic reports out of Europe and China have not been encouraging, which appears to leave the U.S. to power the global economic engine.

Insider Buying Is Still Alive and Well at These 3 Companies

Insider purchases have tapered off from their frenzied pace in late 2018, but here are three names where such buying is evident.

Rules of Biotech Investing Change, and So Must Biotech Investors

One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.

Take a Poker Player's Approach to Playing Small Biotech Stocks

As Kenny Rogers sang, you've got to know when to hold 'em and know when to fold 'em… and sometimes when not to play a hand at all.

3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'

Small-caps have done better than their bigger brethren so far in 2019, and these three stocks are a reason why.

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

Quick takes on fourth-quarter results from these 3 biotech names.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight